0.75 CME Credits. This webinar discusses ADHD and its varied presentations, co-occurring issues, and the importance of accurate assessment for effective treatment.
0.25 CME Credits. In this episode, we explore nine groundbreaking stories in mental health and psychiatric medicine, covering everything from healthcare fraud to the latest advancements in drug trials. First, we dive into the recent charges brought by the US Department of Justice against executives at Done, a California-based telehealth company, for alleged healthcare fraud. Done is accused of prescribing over 40 million Adderall pills to patients without proper evaluation, raising concerns about the balance between increasing mental healthcare access and responsible prescribing practices.
0.25 CME Credits. Highlights from this month include Lumateperone, Lavender, treatment resistant smoking, and Clonidine patches and Tourettes. A new meta analysis published in Psychiatry Research sheds light on a critical question.
0.50 CME Credits. Learn how to address depression in older adults, identify the risk factors and triggers, distinguish depression from normal aging, and explore effective treatment options.
Many families struggle to find OCD treatment for their children. Specialty-trained therapists are limited, and wait lists are usually long. Online therapy is an option, but how well does it work? Today, we discuss a study that examines online cognitive behavioral therapy with exposure and response prevention for kids with OCD.
We interview Victor Hoffbrand on the discovery of folate and look at how this vitamin can help or harm the action of anticonvulsants in bipolar disorder.
This week, the FDA cleared the first blood test for Alzheimer’s disease: the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio.It sounds like a big step forward. Maybe it will prove to be one. But after 22 years of Carlat Report coverage of overhyped tests and treatments, I’ve learned to pause before celebrating “firsts.”
ADHD pharmacology can feel overwhelming. Dozens of formulations. Conflicting data. High stakes for outcomes—and side effects. Each chapter of our Medication Fact Book starts with general tips, and I’m revising the ADHD section for our 8th edition.
In this video, we take an in-depth look at the recently FDA-approved antipsychotic, KarXT, also known by its brand name Cobenfy. This new drug represents a major breakthrough in schizophrenia treatment because, unlike traditional antipsychotics, it doesn’t rely on blocking dopamine receptors. Instead, KarXT works through a muscarinic agonist mechanism, making it a completely different approach to managing schizophrenia and other psychotic disorders.
We understand that you might not have time to read everything. That's why we're offering a special limited-time deal: subscribe to two newsletters of your choice and get 15% off the regular price!
In this video, we explore the use of alpha-2 agonists in the treatment of ADHD, specifically focusing on guanfacine ER (Intuniv) and clonidine ER (Kapvay). These non-stimulant ADHD medications have become viable options for patients who may not tolerate stimulants or have comorbid conditions that make stimulant medications less effective or problematic.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
